A Phase I Study of AC220 for Children with Relapsed or Refractory ALL or AML (IND 111461).

Trial Profile

A Phase I Study of AC220 for Children with Relapsed or Refractory ALL or AML (IND 111461).

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2016

At a glance

  • Drugs Quizartinib (Primary) ; Cytarabine; Etoposide; Methotrexate
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms TACL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Feb 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top